Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives $14.30 Average Price Target from Analysts

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been assigned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $14.30.

VNDA has been the subject of several recent analyst reports. Wall Street Zen cut shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, June 4th.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA opened at $5.36 on Friday. The business’s fifty day moving average price is $6.03 and its 200 day moving average price is $6.94. Vanda Pharmaceuticals has a 12-month low of $4.14 and a 12-month high of $9.94. The stock has a market capitalization of $322.30 million, a PE ratio of -1.32 and a beta of 0.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.16 and a quick ratio of 2.15.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative net margin of 109.99% and a negative return on equity of 32.26%. The company had revenue of $51.72 million during the quarter, compared to analyst estimates of $54.98 million. Equities research analysts forecast that Vanda Pharmaceuticals will post -2.2 EPS for the current year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Torren Management LLC purchased a new stake in Vanda Pharmaceuticals in the 4th quarter worth about $25,000. Russell Investments Group Ltd. grew its stake in Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,328 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Vanda Pharmaceuticals by 3,010.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company’s stock valued at $92,000 after acquiring an additional 10,055 shares in the last quarter. Jain Global LLC acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at about $94,000. Finally, Quarry LP acquired a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at about $53,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.